At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
V710 +1 morebiological
Likely dose
V710 60 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male Japanese Subjects
In Brief
A Phase 1 clinical trial evaluating V710 and Placebo for Staphylococcal Infection. Completed, enrolled 40 participants.
Detailed Summary
This study is to evaluate the safety and immunogenicity of V710 in Japanese male subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStaphylococcal Infection
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
Primary CompletionJun 2008
First PostedAug 2008
TodayJul 2026
First PostedAug 15, 2008
Enrollment StartMar 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.9 years ago
Interventions
V710biological
V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
Placebobiological
Saline placebo (0.5 ml) single injection on Day 1